Abstract
In breast cancer, there is a correlation between tissue factor (TF) expression, angiogenesis and disease progression. TF stimulates tumour angiogenesis, in part, through up-regulation of vascular endothelial growth factor (VEGF). Therefore, this study aimed to establish whether TF stimulates angiogenesis and tumour progression directly and independent of VEGF up-regulation. Initially, the effects of TF and VEGF were assessed on endothelial cell migration (Boyden chamber) and differentiation (tubule formation on Matrigel). Subsequently, MDA-MB-436 breast cancer cells, which produce high levels of both TF and VEGF (western blot analysis), were established in vivo, following which tumours were treated three times per week for 3 weeks with intra-tumoural injections of either anti-VEGF siRNA, anti-TF shRNA, the two treatments combined, or relevant controls. Both VEGF and TF significantly stimulated endothelial cell migration and tubule formation (P < 0.02). Breast cancer xenografts (MDA-MB-436) treated with TF or VEGF-specific agents demonstrated significant inhibition in tumour growth (VEGFsiRNA 61%; final volume: 236.2 ± 23.2 mm3 vs TFshRNA 89%; 161.9 ± 17.4 mm3 vs combination 93%; 136.3 ± 9.2 mm3 vs control 400.4 ± 32.7 mm3; P < 0.005). Microvessel density (MVD), a measure of angiogenesis, was also significantly inhibited in all groups (MVD in control = 29 ± 2.9; TFshRNA = 18 ± 1.1; VEGFsiRNA = 16.7 ± 1.5; both = 12 ± 2.1; P < 0.004), whereas the proliferative index of the tumours was only reduced in the TFshRNA-treated groups (control = 0.51 ± 0.011; TFshRNA = 0.41 ± 0.014; VEGFsiRNA = 0.49 ± 0.013; both = 0.41 ± 0.004; P < 0.008). These data suggest that TF has a direct effect on primary breast cancer growth and angiogenesis, and that specific inhibition of the TF-signalling pathway has potential for the treatment of primary breast cancer.
Similar content being viewed by others
Abbreviations
- CCS:
-
Cumulative Chalkley score
- GF:
-
Growth factor
- HuDMEC:
-
Human dermal microvascular endothelial cells
- MVD:
-
Microvessel density
- PECAM:
-
Platelet endothelial cell adhesion molecule
- TF:
-
Tissue factor
- VEGF:
-
Vascular endothelial growth factor
References
Bluff JE, Brown NJ, Reed MWR, Staton CA (2008) Tissue factor, angiogenesis and tumour progression (review). Breast Cancer Res 10:204–214
Bluff JE, Menakuru SR, Cross SS, Higham SE, Balasubramanian SP, Brown NJ, Reed MW, Staton CA (2009) Angiogenesis is associated with hyperplasia in human ductal breast disease. Br J Cancer 101:666–672
Staton CA, Chetwood AS, Cameron IC, Cross SS, Brown NJ, Reed MWR (2007) The angiogenic switch occurs at the adenoma stage of the adenoma carcinoma sequence in colorectal cancer. Gut 56:1426–1432
Ueno T, Toi M, Koike M, Nakamura S, Tominaga T (2000) Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 83:164–170
Ngo CV, Picha K, McCabe F et al (2007) CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models. Int J Cancer 120:1261–1267
Amarzguioui M, Peng Q, Wiiger MT et al (2006) Ex vivo and in vivo delivery of anti-tissue factor siRNA inhibits mouse pulmonary metastasis of B16 melanoma cells. Clin Cancer Res 12:4055–4061
Rak J, Milsom C, May L, Klement P, Yu J (2006) Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumour neovascularization, and cancer coagulopathy. Semin Thromb Hemost 32:54–70
Abe K, Shoji M, Chen J et al (1999) Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 96:8663–8668
Krajewska E, Lewis CE, Tazzyman S, Chen Y-Y, Staton CA (2010) A novel fragment derived from the beta chain of human fibrinogen, β43-63, is a potent inhibitor of activated endothelial cells in vitro and in vivo. Br J Cancer 102:594–601
Aagaard L, Amarzguioui M, Sun G et al (2007) A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha. Mol Ther 15:938–945
Wang X, Wang M, Amarzguioui M, Liu F, Fodstad Ø, Prydz H (2004) Down-regulation of tissue factor by RNA interference in human melanoma LOX-L cells reduce pulmonary metastasis in nude mice. Int J Cancer 112:994–1002
Filleur S, Courtin A, Ait-Si-Ali S et al (2003) SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 63:3919–3922
Lin X, Yu Y, Zhao H, Zhang Y, Manela J, Tonetti DA (2006) Overexpresion of PKCα is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumour model. Carcinogenesis 27:1538–1546
Staton CA, Stribbling SM, Garcia-Echeverria C, Bury JP, Tazzyman S, Lewis CE, Brown NJ (2007) Identification of key residues involved in mediating the in vivo anti-tumour/anti-endothelial activity of Alphastatin. J Thromb Haemost 5:846–854
Tozer GM, Bhujwalla ZM, Griffiths JR, Maxwell RJ (1989) Phosphorus-31 magnetic resonance spectroscopy and blood perfusion of the RIF-1 tumor following X-irradiation. Int J Radiat Oncol Biol Phys 16:155–164
Staton CA, Brown NJ, Rodgers GR, Corke KP, Tazzyman S, Underwood JCE, Lewis CE (2004) Alphastatin, a 24 amino-acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo. Blood 103:601–606
Morrone FB, Oliveira DL, Gamermann P et al (2006) In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model. BMC Cancer 6:226
Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676
He Y, Chang G, Zhan S, Song X, Wang X, Luo Y (2008) Soluble tissue factor has unique angiogenic activities that selectively promote migration and differentiation but not proliferation of endothelial cells. Biochem Biophys Res Commun 370:489–494
Hobbs JE, Zakarija A, Cundiff DL et al (2007) Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 120:S13–S21
Amirkhosravi A, Meyer T, Warnes G et al (1998) Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor. Thromb Haemost 80:598–602
Sawada M, Miyake S, Ohdama S et al (1999) Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer 79:472–477
Kataoka H, Uchino H, Asada Y et al (1997) Analysis of tissue factor and tissue factor pathway inhibitor expression in human colorectal carcinoma cell lines and metastatic sublines to the liver. Int J Cancer 72:878–884
Mueller BM, Reisfeld RA, Edgington TS, Ruf W (1992) Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 89:11832–11836
Matsumoto G, Kushibiki T, Kinoshita Y et al (2006) Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma. Cancer Sci 97:313–321
Tao J, Tu YT, Huang CZ et al (2005) Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach. Br J Dermatol 153:715–724
Yu JL, May L, Lhotak V et al (2005) Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 105:1734–1741
Uusitalo-Jarvinen H, Kurokawa T, Mueller BM et al (2007) Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol 27:1456–1462
Versteeg HH, Schaffner F, Kerver M et al (2008) Inhibition of tissue factor signaling suppresses tumor growth. Blood 111:190–199
Morris DR, Ding Y, Ricks TK, Gullapalli A, Wolfe BL, Trejo J (2006) Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res 66:307–314
Zhang Y, Deng Y, Luther T et al (1994) Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94:1320–1327
Geβler F, Voss V, Dutzmann S, Gerlach R, Kogel D (2010) Inhibition of tissue factor/protease-activated receptor-2 signaling limits proliferation, migration and invasion of malignant glioma cells. Neuroscience 165:1312–1322
Morrow DA, Murphy SA, McCabe CH, Mackman N, Wong HC, Antman EM (2005) Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. Eur Heart J 26:682–688
Kim SH, Jeong JH, Lee SH, Kim SW, Park TG (2008) Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release 129:107–116
Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu K, Takei Y (2009) Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer 125:2978–2990
Yagi N, Manabe I, Tottori T et al (2009) A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo. Cancer Res 69:6531–6538
Acknowledgments
We gratefully acknowledge the technical support of Jenny Globe, Carmel Nichols and Yvonne Stephenson. This study was supported by Yorkshire Cancer Research (grant number S287).
Conflict of interest
The authors wish to declare a conflict of interest for co-author Dr. Mohammed Amarzguioui. He serves as Research Director for the company SiRNAsense AS, which is currently developing siRNA-based drugs targeting TF.
Author information
Authors and Affiliations
Corresponding author
Additional information
N. J. Brown and C. A. Staton—Joint senior authors.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Bluff, J.E., Amarzguioui, M., Slattery, J. et al. Anti-tissue factor short hairpin RNA inhibits breast cancer growth in vivo. Breast Cancer Res Treat 128, 691–701 (2011). https://doi.org/10.1007/s10549-010-1149-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-010-1149-8